Phosphorylation by glycogen synthase kinase of inhibitor-2 does not change its structure in free state  by Lin, Ta-Hsien et al.
Phosphorylation by glycogen synthase kinase of inhibitor-2
does not change its structure in free state
Ta-Hsien Lina;b, Yi-Chen Chenc, Chia-lin Chyand, Li-huang Tsaye, Tzu Chun Tangb,
Hao-Hsuan Jenge, Fang-Min Linb, Hsien-bin Huange;
aInstitute of Biochemistry, National Yang-Ming University, Shih-pai, Taipei 112, Taiwan, ROC
bDepartment of Medical Research and Education, Taipei Veterans General Hospital, Shih-pai, Taipei 112, Taiwan, ROC
cDepartment of Medical Technology, Tzu Chi University, Hualien 970, Taiwan, ROC
dDepartment of Chemistry, National Dong Hwa University, Hualien 974, Taiwan, ROC
eInstitute of Molecular Biology, National Chung Cheng University, Chia-Yi 621, Taiwan, ROC
Received 13 August 2003; revised 16 September 2003; accepted 18 September 2003
First published online 20 October 2003
Edited by Thomas L. James
Abstract Inhibitor-2 (I2) is a thermostable protein that specif-
ically binds to the catalytic subunit of protein phosphatase-1
(PP1), resulting in the formation of the inactive holoenzyme,
ATP-Mg-dependent phosphatase. Phosphorylation of I2 at
Thr-72 by glycogen synthase kinase-3 (GSK-3) results in acti-
vation of the phosphatase, suggesting that kinase action triggers
conformational change in the complex. In this paper, we char-
acterize the e¡ect of GSK-3 phosphorylation on the structure of
free state I2[1^172] by nuclear magnetic resonance and circular
dichroism spectroscopy, and show that phosphorylation has no
signi¢cant e¡ect on its conformation. We conclude that the
conformational changes of ATP-Mg-dependent phosphatase in-
duced by GSK-3 phosphorylation must depend on the interac-
tions between PP1 and I2.
0 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.




Protein phosphatase-1 (PP1), one of the major mammalian
serine/threonine protein phosphatases, plays a critical role in
the regulation of various cellular functions, including carbo-
hydrate metabolism, protein synthesis, cell cycle, muscle con-
traction and neuronal signaling [1^4]. PP1 occurs in cells as a
holoenzyme and consists of a 37-kDa catalytic subunit com-
bined with a speci¢c regulatory subunit that appears to target
the enzyme to speci¢c subcellular compartments. The catalytic
subunit of PP1 is also regulated by several thermostable pro-
tein inhibitors, including inhibitor-1, DARPP-32 and inhibi-
tor-2 (I2). PP1 is only inhibited by inhibitor-1 and DARPP-32
when both inhibitors are pre-phosphorylated by cAMP-de-
pendent protein kinase (PKA); by contrast, PP1 is inhibited
by I2 without pre-phosphorylation. I2 binds to PP1 to form a
complex that is the ATP-Mg-dependent form of the phospha-
tase, and in turn inhibits enzyme activity. This inactive holo-
enzyme can be reactivated when glycogen synthase kinase-3
(GSK-3) phosphorylates I2 at Thr-72. The mechanism for
reactivation of ATP-Mg-dependent phosphatase is compli-
cated. GSK-3 phosphorylation does not induce the dissocia-
tion of the complex, but triggers a conformational change in
PP1, which rapidly auto-dephosphorylates the phosphorylated
Thr-72 site of I2. Subsequently, the inactive holoenzyme is
slowly converted into an active form [5]. In its dephosphory-
lated form, the active complex then slowly recurs to an inac-
tive state. Di¡erent stages of the reactivation cycle are carried
out by diverse regions of I2 [6]. However, it remains uncertain
whether or not GSK-3 phosphorylation pre-triggers a confor-
mational change in I2, in turn leading to the structural change
of the phosphatase complex. To investigate the conformation-
al state of I2, we prepared GSK-3-phosphorylated I2[1^172]
and characterized its structure by nuclear magnetic resonance
(NMR) and circular dichroism (CD) spectroscopy. Our results
suggest that GSK-3 phosphorylation does not signi¢cantly
change the structure of I2 in the free state. The interactions
between PP1 and I2 may play a vital role in the conforma-
tional change of the complex upon GSK-3 phosphorylation.
2. Materials and methods
2.1. Proteins and reagents
ATP, Tris, dithiothreitol, EDTA, Brij-35 and sodium azide were
obtained from Sigma. 15NH4Cl and [13C]glucose were purchased
from Cambridge Isotope Laboratories. Recombinant GSK-3L was
prepared from Escherichia coli as described [7]. One unit of GSK-3L
was de¢ned as the amount of enzyme that incorporates 1 nmol of
phosphate/min into a PKA-pre-phosphorylated peptide (KRR-
EILSRRPS(P)YR) at 50 WM.
2.2. Preparation of GSK-3-phosphorylated 15N-enriched I2[1^172]
Human recombinant 15N-enriched I2[1^172] was prepared as de-
scribed [8]. I2[1^172] showed similar properties to wild-type I2 with
respect to the IC50 for inhibition of PP1, the formation of an inactive
complex with PP1 and re-activation of PP1 following phosphoryla-
tion by GSK-3L (data not shown). Phosphorylation of 15N-enriched
I2[1^172] by GSK-3L was performed in 50 mM Tris^HCl bu¡er, pH
7.0, containing 0.1 mM EDTA, 0,02% sodium azide, 0.05% Brij-35,
0.2 mM ATP, 2.5 mM magnesium acetate, 15N-enriched I2[1^172]
(5 mg/ml) and GSK-3L (2 U/ml). The reaction was carried out at
30‡C for 2 days, with fresh GSK-3L (2 U/ml) and ATP (0.2 mM ¢nal
concentration) added every 12 h. 15N-enriched phospho-I2[1^172] was
puri¢ed by FPLC using a Mono-Q column (10/10) with a linear salt
gradient from 0.18 to 0.42 M NaCl in 20 mM Tris^HCl bu¡er, pH
7.5, containing 0.2 mM EDTA, 2.0 mM dithiothreitol and 0.02%
(w/v) sodium azide. Fractions (1.5 ml/tube) were collected from 0 to
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45 min. The fractions containing phospho-protein were pooled, dia-
lyzed against water to remove the excess reagents and lyophilized to
powder.
2.3. NMR spectroscopy
For NMR spectroscopy, samples of 0.5 mM 15N-enriched phospho-
I2[1^172] in 90% H2O/10% D2O were prepared in 100 mM phosphate
bu¡ers, pH 6.0, with 0.02% NaN3. 2,2-Dimethyl-2-silapentane-5-sul-
fonic acid was used as the internal chemical shift standard [9,10]. The
¢nal protein sample solution was transferred to a 5-mm Shigemi
NMR tube (Shigemi, Tokyo, Japan) to record the NMR spectra.
2D 1H-15N-heteronuclear single-quantum coherence (HSQC) spectra
were recorded at 296 K on a Bruker AVANCE-500 spectrometer
equipped with a 5-mm inverse triple resonance (1H/13C/BB), z-axis
gradient probe. Water suppression was achieved by applying
WATERGATE sequence [11]. Quadrature detection in the indirectly
detected dimension was accomplished using the States-TPPI method
[12]. Spectral width was 1500 Hz in both the direct (1H) and indirect
(15N) dimensions. A total of 128 time increments were recorded with
32 transients for each increment. Spectra were processed using
XWINNMR and analyzed using AURELIA [13] on an SGI work-
station.
2.4. CD spectroscopy
CD spectra were recorded using a Jasco 715 spectropolarimeter
with a thermal circulator accessory. The optical rotation was cali-
brated using d-10-camphorsulfonic acid at wavelengths of 192.5 and
290 nm. The wavelength was calibrated with benzene vapor. All mea-
surements were performed in quartz cells with a path length of 0.01
cm. The protein concentration of the samples was 1.0 mg/ml. Data
were collected for wavelengths from 190 to 260 nm at 1-nm incre-
ments. Reported CD spectra represent the average of at least three
individual samples and three repeated measurements of each sample.
Baseline corrections for the spectra were made by using solutions
containing DMPC. All measurements were carried out at
25.0R 0.2‡C. Secondary structure analysis was performed using online
software, website: Dichroweb from BBRC Centre for Protein and
Membrane Structure and Dynamics [14,15].
3. Results
3.1. Phosphorylation of 15N-enriched I2[1^172] by GSK-3L
The two rat brain isoforms of GSK-3, GSK-3K and GSK-
3L, di¡er in their ability to phosphorylate I2 at Thr-72 [16,17].
GSK-3L is a better I2 kinase than GSK-3K. Under the present
experimental conditions, however, the yield of phosphorylated
I2 by GSK-3L was low. Therefore, both fresh GSK-3L and
ATP were added every 12 h during the phosphorylation re-
action. After 2 days, about 70% of the 15N-enriched I2[1^172]
was phosphorylated, as judged by analysis of the ion exchange
chromatography fractions (Fig. 1a). Sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE) shows that
15N-enriched phospho-I2[1^172] has a lower mobility on the
gel (Fig. 1b), and that phospho-I2[1^172] was puri¢ed to
greater than 96% homogeneity by FPLC using a Mono-Q
column (data not shown).
The e¡ect of phosphorylation on the conformational behav-
ior of I2[1^172] was studied by CD spectroscopy. Fig. 2 shows
an overlay of the CD spectra of I2[1^172] and phospho-I2[1^
172]. These two spectra are almost identical, suggesting that
the global conformation of I2[1^172] is not in£uenced by
phosphorylation. Analysis of the secondary structure from
the CD spectra shows that both I2[1^172] and phospho-
I2[1^172] have a mostly non-structural conformation. The
NMR results (Fig. 3) also support this inference. Clearly,
the chemical shifts of the backbone amides and the 15N res-
onances for most of the residues of I2[1^172] remain un-
changed when Thr-72 is phosphorylated by GSK-3. Working
from previously assigned backbone amide proton and 15N
Fig. 1. a: Puri¢cation of phospho-I2[1^172] by FPLC on a Mono-Q
column. b: SDS^PAGE analysis of phospho-I2[1^172] in fractions
40^47 from panel a. Molecular weight markers are phosphorylase b
(97 kDa), bovine serum albumin (76 kDa), ovalbumin (45 kDa),
carbonic anhydrase (30 kDa), trypsin inhibitor (21.5 kDa), and lyso-
zyme (14.3 kDa).
Fig. 2. An overlay of the CD spectra of I2[1^172] (black) and phos-
phorylated I2[1^172] (red).
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chemical shifts of I2[1^172] [8], residues with signi¢cant chem-
ical shift changes (S71, T72, S76, D125) were identi¢ed by a
graphic mapping approach. The chemical shift changes of
these residues may be due to the electrostatic e¡ect of the
phosphate group or to phosphorylation-induced conforma-
tional change or to a combination of both [18]. Since only a
few residues exhibit signi¢cant chemical shift changes, it is
unlikely that phosphorylation of I2[1^172] at Thr-72 has a
signi¢cant e¡ect on the global conformation of I2[1^172]. Be-
sides, these residues are randomly distributed in the primary
sequence, and not located consecutively, which suggests that
even local conformational changes would probably occur. Our
interpretation of the results is therefore that the phosphoryla-
tion-induced chemical shift changes are mainly caused by the
through-space electrostatic e¡ects of the phosphate group. If
this is correct, then the residues with signi¢cant chemical shift
changes should be located in the spatial vicinity of the phos-
phorylation site.
4. Discussion
Previous studies on the e¡ect of phosphorylation on the
conformation of proteins have yielded diverse results [19^
23], with some supporting a change of conformation and
others reporting no e¡ect at all. In most cases, when phos-
phorylation causes conformational change, long-term alloste-
ric changes may occur [19^22]. In the case of I2, the confor-
mation of which is a random coil except for a short K-helix
that spans the region from residue 132 to 142 [8], our NMR
and CD spectroscopy data suggest that no signi¢cant confor-
mational changes were induced after the Thr-72 site of I2[1^
172] was phosphorylated by GSK-3. Using £uorescence tech-
niques, Picking et al. [5] demonstrated that phosphorylation
by GSK-3 resulted in a conformational change of I2, but this
e¡ect was induced only when I2 had formed a complex with
PP1. Furthermore, they pointed out that the free phosphory-
lated I2 will eventually relax back to its native conformational
state. Bearing in mind that our NMR and CD data were
obtained for I2 in its free state and in equilibrium, the present
results are consistent with those of Picking et al. [5]. We con-
clude that the binding of I2 to PP1 is critical, and that the
interactions between PP1 and I2 may play a vital role in the
conformational change of the complex upon GSK-3 phos-
phorylation.
Acknowledgements: This work was supported by the National Science
Council of the Republic of China (NSC91-2311-B-010-002 and
NSC92-2320-B-194-005) and the Taipei Veterans General Hospital,
Taiwan, Republic of China.
References
[1] Cohen, P. (1989) Annu. Rev. Biochem. 58, 453^508.
[2] Shenolikar, S. and Nairn, A.C. (1991) Adv. Second Messenger
Phosphoprotein Res. 23, 1^121.
[3] Shenolikar, S. (1994) Annu. Rev. Cell Biol. 10, 55^86.
[4] Wera, S. and Hemmings, B.A. (1995) Biochem. J. 311, 17^29.
[5] Picking, W.D., Kudlicki, W., Kramer, G., Hardesty, B., Vanden-
heede, J.R., Merlevede, W., Park, I.K. and DePaoli-Roach, A.
(1991) Biochemistry 30, 10280^10287.
Fig. 3. An overlay of the 2D 1H-15N-HSQC spectra of I2[1^172] (black) and phosphorylated I2[1^172] (red). Residues with signi¢cant chemical
shift changes are labeled.
FEBS 27731 5-11-03 Cyaan Magenta Geel Zwart
T.-H. Lin et al./FEBS Letters 554 (2003) 253^256 255
[6] Park, I.K. and DePaoli-Roach, A.A. (1994) J. Biol. Chem. 269,
28919^28928.
[7] Wang, Q.M., Fiol, C.J., DePaoli-Roach, A.A. and Roach, P.J.
(1994) J. Biol. Chem. 269, 14566^14574.
[8] Huang, H.B., Chen, Y.C., Tsai, L.H., Wang, H.C., Lin, F.M.,
Horiuchi, A., Greengard, P., Nairn, A.C., Shiao, M.S. and Lin,
T.H. (2000) J. Biomol. NMR 17, 359^360.
[9] Wishart, D.S., Bigam, C.G., Yao, J., Abildgaard, F., Dyson,
H.J., Old¢els, E., Markley, J.L. and Sykes, B.D. (1995) J. Bio-
mol. NMR 6, 135^140.
[10] Wishart, D.S. and Sykes, B.D. (1994) Methods Enzymol. 239,
363^392.
[11] Piotto, M., Saudek, V. and Sklenar, V. (1992) J. Biomol. NMR
2, 661^665.
[12] Marion, D., Ikura, M., Tschudin, R. and Bax, A. (1989) J. Magn.
Reson. 85, 393^399.
[13] Neidig, K.-P., Geyer, M., Gorler, A., Antz, C., Sa¡rich, R.,
Beneike, W. and Kalbitzer, R. (1995) J. Biomol. NMR 6, 255^
270.
[14] Lobley, A. and Wallace, B.A. (2001) Biophysical J. 80, 373a.
[15] Lobley, A. and Whitmore, L. (2002) Bioinformatics 18, 211^212.
[16] Woodgett, J.R. (1990) EMBO J. 9, 2431^2438.
[17] Wang, Q.M., Park, I.K., Fiol, C.J., Roach, P.J. and DePaoli-
Roach, A.A. (1994) Biochemistry 33, 143^147.
[18] Radhakrishnan, I., Perez-Alvarado, G.C., Dyson, H.J. and
Wright, P.E. (1998) FEBS Lett. 430, 317^322.
[19] Johnson, L.N. and O’Reilly, M. (1996) Curr. Opin. Struct. Biol.
6, 762^769.
[20] Russo, A., Je¡rey, P.D. and Pavletich, N.P. (1996) Nat. Struct.
Biol. 3, 696^700.
[21] Lin, K., Rath, V.L., Dai, S.C., Fletterick, R.J. and Hwang, P.K.
(1996) Science 273, 1539^1541.
[22] Birck, C., Mourey, L., Gouet, P., Fabry, B., Schumacher, J.,
Rousseau, P., Kahn, D. and Samama, J.-P. (1999) Structure 7,
1505^1515.
[23] Seavers, P.R., Lewis, R.J., Brannigan, J.A., Verschueren,
K.H.G., Murshudov, G.N. and Wilkinson, A.J. (2001) Structure
9, 605^614.
FEBS 27731 5-11-03 Cyaan Magenta Geel Zwart
T.-H. Lin et al./FEBS Letters 554 (2003) 253^256256
